Oral Answers to Questions

Crispin Blunt Excerpts

Tuesday 7th March 2023 Commons Chamber

[Steve Barclay]

The hon. Gentleman raises an extremely important subject. As well as the additional investment and extra workforce we are putting into mental health, we are looking at this issue as part of our strategies in other areas—for example, our suicide strategy—and examining our capital investment. There is a range of measures to address this very important issue.

[Crispin Blunt (Reigate) (Con)]

My right hon. Friend is aware of the evidence on the use of psychedelic drugs for more effective mental health care. Last month Australia, having assessed the evidence on psilocybin, started the rescheduling process, and Australians suffering from depression will be able to access this medicine from July. In the USA, the Food and Drug Administration has recognised psilocybin as a breakthrough therapy for depression. In Canada, the special access programme allows physicians to request a licence for assisted therapy under certain conditions. Our drug laws remain based on a 50-year-old, unevidenced, prejudiced assessment and nothing else. The Home Office has never commissioned evidence on psilocybin. Does my right hon. Friend understand that this is a primary public health issue, on which he should lead?

[Steve Barclay]

I recognise the close interest my hon. Friend takes in this matter, and he is right to draw the House’s attention to international best practice. I agree that we should take an evidence-based approach in which we look at the data shared with regulators in other countries, such as Australia. I am happy to draw the point he makes to the attention of our regulators.